|
Place de cotation: AMSTERDAM
STOCK EXCHANGE
OctoPlus NV is a Netherlands-based
drug delivery and drug development company. The Company’s activities include
pharmaceutical development services, drug delivery technologies and product
development. The products and drug delivery divisions focus on developing
pharmaceutical products, including Locteron, for treating chronic hepatitis
C viral infections; OP-145 CSOM; OP-286 CR; HBVOctoVAX, a vaccine against
hepatitis B infections, and JEV-OctoVAX, a vaccine against Japanese encephalitis.
The product development division specializes in providing services to life
sciences companies in the field of drug formulation. On October 6, 2008
Octoplus sold the commercial rights of Locteron to Biotex Therapeutics
Inc. As of December 31, 2008, OctoPlus NV had the following subsidiaries:
OctoShare B.V., OctoPlus Development B.V., OctoPlus Technologies B.V.,
OctoPlus Sciences B.V., OctoPlus PolyActive Sciences B.V. (incorporated
on September 9, 2008), Chienna B.V. and OctoPlus Inc.
http://www.octoplus.nl/ |